[{"orgOrder":0,"company":"Syndesi Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"SDI-118","moa":"SV2A","graph1":"Neurology","graph2":"Phase I","graph3":"Syndesi Therapeutics","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":1,"dosageForm":"Capsule","sponsorNew":"Syndesi Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Syndesi Therapeutics \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Syndesi Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depres...

                          Brand Name : SDI-118

                          Molecule Type : Small molecule

                          Upfront Cash : $130.0 million

                          March 01, 2022

                          Lead Product(s) : SDI-118

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : AbbVie Inc

                          Deal Size : $1,000.0 million

                          Deal Type : Acquisition

                          blank